IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer
Advanced Science · 2023-06 · 10 (17)
DOI: 10.1002/advs.202206889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.04.2023. Verfasst von Deng Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncogenes and Related Genes, Renji-Med-X Stem Cell Research Center, Shanghai Cancer Institute & Department of Urology, Ren Ji…. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Pilot Program for Basic Research-Shanghai Jiao Tong University, Program of Shanghai Academic/Technology Research Leader.
Abstract (Originalsprache)
Great attention is paid to the role of androgen receptor (AR) as a central transcriptional factor in driving the growth of prostate cancer (PCa) epithelial cells. However, the understanding of the role of androgen in PCa‐infiltrated immune cells and the impact of androgen deprivation therapy (ADT), the first‐line treatment for advanced PCa, on the PCa immune microenvironment remains limited. On the other hand, immune checkpoint blockade has revolutionized the treatment of certain cancer types, but fails to achieve any benefit in advanced PCa, due to an immune suppressive environment. In this study, it is reported that AR signaling pathway is evidently activated in tumor‐associated macrophages (TAMs) of PCa both in mice and humans. AR acts as a transcriptional repressor for IL1B in TAMs. ADT releases the restraint of AR on IL1B and therefore leads to an excessive expression and secretion of IL‐1β in TAMs. IL‐1β induces myeloid‐derived suppressor cells (MDSCs) accumulation that inhibits the activation of cytotoxic T cells, leading to the immune suppressive microenvironment. Critically, anti‐IL‐1β antibody coupled with ADT and the immune checkpoint inhibitor anti‐PD‐1 antibody exerts a stronger anticancer effect on PCa following castration. Together, IL‐1β is an important androgen‐responsive immunotherapeutic target for advanced PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med-X Stem Cell Research Center, Shanghai Cancer Institute & Department of Urology, Ren Ji Hospital, School of Medicine and School of Biomedical Engineering, Sh…
- School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China.
- School of Biomedical Engineering, ShanghaiTech University, Shanghai, 201210, P. R. China.
- Mabspace Biosciences (Suzhou) Co. Limited, Suzhou, 215123, P. R. China.
ORCID-Profile: Wei-Qiang Gao, Helen He Zhu
Förderung
- National Natural Science Foundation of China
- Shanghai Pilot Program for Basic Research-Shanghai Jiao Tong University
- Program of Shanghai Academic/Technology Research Leader
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support
- Innovative research team of high-level local universities in Shanghai
- National Key R&D Program of China
- 111 project
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Wang, D., Cheng, C., Chen, X., Wang, J., Liu, K., Jing, N., Xu, P., Xi, X., Sun, Y., Ji, Z., Zhao, H., He, Y., Zhang, K., Du, X., Dong, B., Fang, Y., Zhang, P., Qian, X., Xue, W., …, & Zhu, H. H. (2023). IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer. Advanced Science, 10(17). https://doi.org/10.1002/advs.202206889
Vancouver
Wang D, Cheng C, Chen X, Wang J, Liu K, Jing N, et al. IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer. Advanced Science. 2023;10(17). doi:10.1002/advs.202206889
BibTeX
@article{Wang2023,
author = {Wang, Deng and Cheng, Chaping and Chen, Xinyu and Wang, Jinming and Liu, Kaiyuan and Jing, Na and Xu, Penghui and Xi, Xialian and Sun, Yujiao and Ji, Zhongzhong and Zhao, Huifang and He, Yuman and Zhang, Kai and Du, Xinxing and Dong, Baijun and Fang, Yuxiang and Zhang, Pengcheng and Qian, Xueming and Xue, Wei and Gao, Wei-Qiang and Zhu, Helen He},
title = {IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {17},
doi = {10.1002/advs.202206889}
}
EUVIMED